A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) — Stella
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(37 sites)
United States
City of Hope /ID# 261468, Duarte, California
City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669, Irvine, California
UC Irvine /ID# 255673, Orange, California
The University of Chicago Medical Center /ID# 255674, Chicago, Illinois
Alliance for Multispecialty Research LLC Kansas City Oncology /ID# 256830, Merriam, Kansas
Norton Cancer Institute /ID# 260775, Louisville, Kentucky
Henry Ford Hospital /ID# 255803, Detroit, Michigan
Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041, Saint Louis Park, Minnesota
Washington University-School of Medicine /ID# 255720, St Louis, Missouri